| The Iodine Group | ||
|
Home | Orthoiodosupplementation | Body | Disease | Special | Overviews |
||
|
|
Ball
3,5-Diiodo-L-thyronine (T2) has selective thyromimetic effects in vivo and in vitro.Ball SG, Sokolov J, Chin WW. J Mol Endocrinol. 1997 Oct;19(2):137-47.
"Recent data have
suggested that the iodothyronine, 3,5-diiodo-l-thyronine (T2),
has selective thyromimetic activity. In vivo, T2 has been shown
to suppress TSH levels at doses that do not produce significant
peripheral manifestations of thyroid hormone activity.
Furthermore, T2 has been shown to produce smaller increments in
peripheral indices of thyroid status than does T3, when doses
resulting in equivalent suppression of circulating TSH are
compared. We have assessed the selective thyromimetic activity of
T2 in vivo and in vitro, and performed in vitro studies to assess
the potential molecular basis for these selective properties. T2
was 100-fold less potent than T3 in stimulating GH mRNA levels in
GH3 cells. In contrast, the iodothyronines were almost equivalent
in their ability to downregulate TRbeta2 mRNA levels in this cell
line. Both 3,3'-diiodo-L-thyronine and thyronine exhibited no
significant thyromimetic effects on either process. In vivo,
doses of T2 and T3 that were equivalent in their induction of
hepatic malic enzyme (ME) mRNA did not produce equivalent
suppression of circulating TSH, with T2 being only 27% as
effective as T3. T2 was up to 500-fold less potent than T3 in
displacing [125I]-T3 from in vitro translated specific nuclear
receptors (TRs) and GH3 cell nuclear extracts. Electrophoretic
mobility shift assays, assessing the ability of T2 to produce
dissociation of TRbeta1 homodimers from inverted palindrome T3
response elements, indicated that T2 was also 1000-fold less
potent than T3 in this respect. These data confirm that T2 has
significant thyromimetic activity, and that this activity is
selective both in vivo and in vitro. However, there are no data
to support a selective central effect, T2 being relatively more
potent in stimulating hepatic ME mRNA than in suppression of TSH
in vivo. The basis for this differential thyromimetic activity is
not selective affinity of the different TR isoforms for T2, or
divergent properties of T2 in competitive binding and functional
assays in vitro." |
|
Home | Orthoiodosupplementation | Body | Disease | Special Topics | OverviewsThe Iodine Group | Books | Disclaimers | Contact Us | SearchCopyright: Zoe, 2006. |
||